ProtoKinetix Adds New Board Member

VANCOUVER, British Columbia--()--ProtoKinetix (OTCQB:PKTX) (www.protokinetix.com) today announced that Peter K. Jensen, LL.B., BCL, B.Sc., Chairman of RepliCel Life Sciences and practicing lawyer, was appointed to the company’s board of directors. The Company has also issued 1,000,000 shares of common stock of the Company and a three-year option for 1,000,000 shares of common stock exercisable at $0.05US per share to Mr. Jensen in connection with his appointment to the Board and for services to the Company.

“Peter has extraordinary biotechnology and business expertise, and we are delighted that he is joining ProtoKinetix’s board of directors”

“Peter has extraordinary biotechnology and business expertise, and we are delighted that he is joining ProtoKinetix’s board of directors,” said Clarence Smith, ProtoKinetix Chairman.

About Peter Jensen

Mr. Jensen is married with five children. He acquired his Bachelor of Science and Law degrees at McGill University in Montreal, Quebec, with a dual degree in common and civil law. His science degree is in the field of biology (marine biology and ecology). He also conducted diabetes research at the Royal Victoria Hospital (Montreal), was a director of a community medical clinic for three years and ran the McGill legal clinic for two years.

In 1981 Mr. Jensen commenced the practice of law in the corporate and securities fields in British Columbia. Mr. Jensen has a wide range of legal counseling experience internationally. Mr. Jensen has an understanding of the particular nature of the challenges facing corporate management as he has been and is a director of a number of private and publicly traded companies, has been a board member of companies with capitalization in the hundreds of millions and has assisted in the raising of capital in ranges of up to one hundred million dollars in Canada, the United States, Europe, and the Orient.

In addition to continuing an active legal practice at Beadle Raven LLP, Mr. Jensen is Chairman of RepliCel Life Sciences. RepliCel is a publicly listed cell replication company which recently struck an agreement with Shiseido of Japan to license Shiseido with RepliCel’s leading edge cell replication technology. Mr. Jensen is Chairman of Solar Flow-Through Limited Partnerships I, II, III and IV which are installing solar power arrays in Ontario under the Ontario FIT program. Mr. Jensen is also a director of a British Columbia public agricultural land banking company, New Age Farms, and of a California public company, bBooth Inc, offering music booth recording facilities to the public.

About ProtoKinetix

ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™). These molecules have been demonstrated to protect cells against hostile conditions that are present in all areas of transplantation including regenerative medicine.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

Clarence E. Smith – President and CEO

Contacts

ProtoKinetix, Inc.
Blair Henderson, 604-926-6627

Recent Stories

RSS feed for ProtoKinetix, Inc.

ProtoKinetix, Inc.